

Paper V



Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches[☆]



Osman A. Gani, Balmukund Thakkar, Dilip Narayanan, Kazi A. Alam, Peter Kyomuhendo, Ulli Rothweiler, Veronica Tello-Franco, Richard A. Engh^{*}

The Norwegian Structural Biology Centre, Department of Chemistry, University of Tromsø, Tromsø, Norway

ARTICLE INFO

Article history:

Received 15 March 2015

Received in revised form 8 May 2015

Accepted 11 May 2015

Available online 19 May 2015

Keywords:

Structure based drug design

ABL

Aurora

Drug repurposing

Crystal structure

Cheminformatics

ABSTRACT

In just over two decades, structure based protein kinase inhibitor discovery has grown from trial and error approaches, using individual target structures, to structure and data driven approaches that may aim to optimize inhibition properties across several targets. This is increasingly enabled by the growing availability of potent compounds and kinome-wide binding data. Assessing the prospects for adapting known compounds to new therapeutic uses is thus a key priority for current drug discovery efforts. Tools that can successfully link the diverse information regarding target sequence, structure, and ligand binding properties now accompany a transformation of protein kinase inhibitor research, away from single, block-buster drug models, and toward “personalized medicine” with niche applications and highly specialized research groups. Major hurdles for the transformation to data driven drug discovery include mismatches in data types, and disparities of methods and molecules used; at the core remains the problem that ligand binding energies cannot be predicted precisely from individual structures. However, there is a growing body of experimental data for increasingly successful focussing of efforts: focussed chemical libraries, drug repurposing, polypharmacological design, to name a few. Protein kinase target similarity is easily quantified by sequence, and its relevance to ligand design includes broad classification by key binding sites, evaluation of resistance mutations, and the use of surrogate proteins. Although structural evaluation offers more information, the flexibility of protein kinases, and differences between the crystal and physiological environments may make the use of crystal structures misleading when structures are considered individually. Cheminformatics may enable the “calibration” of sequence and crystal structure information, with statistical methods able to identify key correlates to activity but also here, “the devil is in the details.” Examples from specific repurposing and polypharmacology applications illustrate these points. This article is part of a Special Issue entitled: Inhibitors of Protein Kinases.

© 2015 Elsevier B.V. All rights reserved.

1. Introduction

The first protein kinase structure determinations [1,2] initiated the era of kinase inhibitor structure based drug design. The rho-kinase inhibitor HA1077 [3] (Fasudil) was approved in Japan in 1995, but it was the approval of imatinib (Glivec) [4,5] in 2001 that firmly established protein kinases as high priority drug targets, particularly in oncology. Since then, the structural information available for drug design, has grown massively. Now, structure and data driven approaches even may rationally attempt to optimize target selectivity profiles based on biological data, using information from thousands of known inhibitors. Assessing the prospects for adapting known compounds to new therapeutic uses is thus a key priority for current drug discovery efforts, and repurposing or redesigning known compounds may be most

efficient [6–11]. Tools that can successfully link the diverse information regarding target sequence, structure, and ligand binding properties have the potential to transform kinase inhibitor research away from single, block-buster drug models, and into “personalized” and other niche areas where also academic groups may specialize.

An understanding of “where to look” aids these efforts, and the evaluation of protein kinase target similarity is part of this. This is most easily quantified by sequence, and such a bioinformatics approach is familiar to the broadest audience, usually using phylogenetic trees of whole sequences. Broad and useful similarity classification can be made by identifying key binding sites, supporting an evaluation of resistance mutations, and the use of surrogate proteins to aid experiment. However, ligand design requires an understanding of ligand–target interactions, and this is most directly a structural topic. Although structural evaluation uses and offers more information, the flexibility of protein kinases, and differences between the crystal and physiological environments may make the use of crystal structures misleading when structures are considered individually. For use of structures collectively, informatics

[☆] This article is part of a Special Issue entitled: Inhibitors of Protein Kinases.

^{*} Corresponding author.

E-mail address: Richard.Engh@uit.no (R.A. Engh).

methods must be used. Such methods may enable the “calibration” of sequence and crystal structure information, with statistical methods able to identify key correlates to activity but also here, it is still true that “the devil is in the details” [12].

2. Results and discussion

2.1. Similarity by sequence

2.1.1. Key residues

A direct way to visualize some key aspects of protein kinase similarity is simply to plot the distribution of key residues on a phylogenetic tree with the same layout as the original kinome analysis of Manning et al. [13], which has become intimately familiar to most protein kinase researchers. Thus, the gatekeeper distribution (Fig. 1A) readily shows the clustering of the most common gatekeeper residues: Met, Thr, Leu, and Phe, and also identifies some potentially surprising connections, such as Flt3 with CMGC kinases. Less well known is the conservation of the “gatekeeper + 2 residue” (Fig. 1B), which is usually an aromatic amino acid (tyrosine or phenylalanine, sometimes tryptophan as in BRAF) or leucine. This site is particularly interesting as one that is often found in drug resistant cancers, and in CML is often the one with the most rapid appearance [14]. Other key residues include the glycine residues of the glycine-rich loop, with the consensus sequence GxGxxG. Although the function of these residues is not entirely clear, besides sterically allowing ATP binding [15], they contribute the high flexibility seen for the glycine-rich loop in response to inhibitor binding, with possibly enhanced flexibility for Abl1, with its GGGxxG sequence, and reduced flexibility for protein kinases lacking the third glycine (Fig. 1C; the first two are most highly conserved).

Although plots of individual residues are informative with respect to specific features, they cannot suggest overall inhibitor binding similarities between kinases. On the other hand, the phylogenetic tree itself does represent overall homology, but not specifically for inhibitor binding. An intermediate similarity measure would be the use of pseudosequences, chosen to represent residues important for inhibitor binding. The choice of these residues is however not unique. The differing binding geometries of different inhibitors involve different side chains, and many residues that play a role in binding may make no contact at all, but may influence other properties, such as flexibility.

Fig. 2 shows pseudosequence similarity plots for Aurora B and Abl kinases, calculated using the Needleman–Wunsch algorithm and a Blosum62 similarity matrix as implemented in Mathematica, on a pseudosequence of key residues. For comparison, Fig. 2 also shows the correlations of inhibitor binding energies for the same kinases with the protein kinases in the Ambit kinase profiling set of 2011 [16]. These pseudosequences show the Aurora kinases to be quite unique (Fig. 2A), with some cognates in the CAMK group, rather more specific than the kinase binding data show (Fig. 2B). In contrast, Abl pseudosequence similarity clusters within the tyrosine kinase subfamily (Fig. 2C), with better agreement with the inhibitor data.

2.2. Similarity by structure

Sequence determines structure, and structure determines binding energetics, so structure represents a higher level of information content for evaluating target similarity; efforts to contribute to and use the information from worldwide Protein Data Bank [17,18] reflect its central importance. However, even though sequence determines structure, a unique sequence does not guarantee a unique structure, despite a persistent prejudice to the contrary. Throughout the period of protein crystallography, protein structures have been known to be dynamic and dependent on total chemical composition (i.e. posttranslational modifications), environment (pH, temperature, ionic strength), binding

partners (proteins, small molecules), and so on. As the PDB grows, more and more of these effects can be recognized and characterized, enabling meaningful PDB wide searches, e.g. repurposing opportunities [19,20]. Because the structural variability is large compared to what determines ligand binding energetics, conformational space remains enormous compared to the size of the PDB.

Many of the key states of protein kinases have been determined; key activity modulation mechanisms involving especially “helix C”, the activation loop (including phosphorylation and the “DFG-in”, “DFG-out”, and intermediate states), and the glycine-rich loop have been identified. However, their observation in association with a particular inhibitor does not guarantee that that is the only, or even the lowest energy state of the complex. Crystallization conditions, the energy of crystal packing contacts, and the state of the protein used for crystallization can be major determinants for the observed state. Compounding this problem is the fact that inhibitors are usually assumed to possess a single binding geometry: 1) Crystals lacking the resolution to identify structural heterogeneity will lead to a single modeled structure, as a rule, 2) inhibitors that bind with structural heterogeneity may cause such a moderate resolution, and 3) optimization of crystallization conditions to maximize resolution may be a search for conditions to eliminate alternate binding geometries that occur in a biological environment. The examples presented in the section illustrate some of the difficulties.

2.2.1. Understanding the binding mode(s) of VX680

The inhibitor VX680 (or MK0457), originally identified as an Aurora kinase inhibitor, has been in several clinical trials for cancer indications including solid tumors [21], leukemias [22–24], and lung cancer, as reflected by its low nanomolar inhibition of Abl, Aurora, and Flt3 kinases, including the drug resistant Abl mutant T315I [16]. The cross reactivity between Abl and Aurora is in apparent contradiction to their overall similarity (unlike the cross reactivity between Aurora and Flt3, which is identified, Fig. 2). One notable feature that Aurora and Abl kinases share when binding to VX680 is a reconfiguration of the glycine-rich loop to form a pi–pi stacking arrangement between the inhibitor and the highly conserved aromatic amino acid at the beta-hairpin turn of the loop. If the two kinases shared an anomalous propensity for such a reconfiguration, the cross-reactivity might be explained. And indeed, Abl is unusually glycine-rich, with a GGGxYG motif. But Aurora’s GxGxFG is not remarkable in this respect. Further, VX680 is seen bound to Aurora both with and without the pi–pi interaction (Fig. 3). Mutational studies indicate that the pi–pi interaction is important for binding independent of binding to co-factor TPX2 [25]. Abl kinase has been observed in DFG-in, DFG-out, and intermediate states, and SRC-like, as recently reviewed [26]. VX680 binds to Abl kinase in both active and inactive forms (Fig. 3b). This is consistent with measurements of VX680 binding to phosphorylated Abl variants by Ambit Biosciences in 2011 [16]. Here, phosphorylation of the Abl kinase domain had only small effects on binding of VX680, and variously tightened or weakened binding, depending on the mutant form of the kinase. In contrast to the weak effect of phosphorylation, mutation of the hinge aromatic (gatekeeper + 2, see Fig. 1B) residue from phenylalanine to leucine or especially isoleucine weakened binding by two to three orders of magnitude. One clear consequence of these observations is that crystal structures may not, in isolation, be considered to be proof of the “true” or even minimum energy binding geometry as it occurs *ex crystallo*. Another may be that the anomalous cross reactivity of binding to both Abl and Aurora kinases stems from a propensity to bind to multiple target structures.

2.2.2. Understanding the polypharmacology of crizotinib

Crizotinib was designed [33] as a dual inhibitor of Alk and Met kinases (low or subnanomolar for Alk, Met, but also MERTK, ROS1, Ephb6, Axl, and Abl kinases [16]). Inhibitor correlation analyses show moderate similarities for Alk and Met (see also 2.3 Cheminformatics,




Fig. 1. Distributions of key residues in the human kinome. A) the gatekeeper, B) the hinge residue two residues downstream from the gatekeeper, and C) the third glycine position of the GxGxxG motif.

below). The availability of X-ray structures for crizotinib in complex with both Alk (PDB ID: 2YFX [34]) and Met (PDB ID: 2WGJ [33]) might explain the similarity. Examination of the structures shows that, although the hinge binding and overall geometry are the same,

crizotinib has no side chain interactions in common between the structures. Thus, the similarity is not likely to be clearly reflected in a sequence based analysis. In this case, binding pocket analyses might be the proper approach. However, comparison of the available structures




Fig. 2. Pseudosequence similarity plots for Aurora B (2A) and Abl (2C), compared to the inhibition profile correlations of Aurora B (2B) and Abl (2D) with other tested kinases (see text).

for Met and Alk show that they have been crystallized in very different states, especially with respect to activation loop geometries, with no clear choice for making direct comparisons (Fig. 4).

2.2.3. Docking to similar kinases

The examples above illustrate how the flexibilities of target structures complicate binding pocket analysis. Generally, even high

resolution crystal structures will represent at best a subset of the binding site conformations that are energetically available for ligand binding. Docking provides a way to observe specific effects that may arise in automated methods, and indeed, automated docking procedures fail more often than not even with correct target structure, at least for protein kinases [35], and the procedures may be tailored to optimize results [36,37]. For unknown protein kinase target structures, homology




Fig. 3. Overlay of VX680 structures show variations in the A) glycine-rich loop and B) DFG configurations. Abl DFG-in structures are colored with shades of blue (ABL1, PDB ID: 2F4J [27] and PDB ID: 3E5A [28]; ABL2: PDB ID: 2XYN [29]), ABL1 DFG-out structures in cyan (PDB ID: 4ZOG); Aurora structures in shades of purple (Aurora A, PDB ID: 4JBQ [30]; Aurora B, PDB ID: 4B8M and PDB ID: 4AF3 [31]), and PKA based Aurora mimic in pink (PDB ID: 3AMB [32]).

modeling introduces additional error, such that it may be better to dock against the template structure than the modeled target. However; the modeled targets may even perform better [38]. Because of the uncertainties, experienced medicinal chemists will view docking results skeptically, but they will view them, because inspection of the range of docking poses and characteristics of the binding site will generate ideas for further optimization and testing. Docking done with diverse methods and diverse targets provides a test for the robustness and variability of the predictions.

Here we show tests of docking ROCK1 inhibitors to ROCK1, PKA, and PKA–ROCK1 hybrid target structures (Fig. 5), looking at the predicted minimum energy poses as functions of target structure, minimization of target structure, protonation state of the inhibitor. Although only a small fraction of docking experiments reproduced the experimental binding pose in its entirety (dark green), somewhat over half reproduced at least the hinge binding interactions (dark and light green), and a clear majority predicted at least some hinge binding (yellow and greens). The failure of staurosporine to dock successfully in any target except its parent structure (and here only with XP precision docking) is notable. Because staurosporine, with its extended planar and aromatic structure, significantly expands the binding site [39],




Fig. 4. Superposition of ALK and MET structures. The ALK structures in the PDB (here with a single representative in red) share a configuration with the activation loop locked in a helix with the phosphorylation site tyrosine (red sticks) oriented toward the back. The MET structures cluster into several groups (green and violet), DFG-in, DFG-out and intermediate states.

docking requires adequate prediction of flexibility prediction for the target, as has been noted previously [40,41]. The target 1SVG also usually failed to predict hinge binding. Here, due to definition of the pocket grid based on the extent of the native ligand, the more extended inhibitor of 1SVG led to a pocket that included more residues distant from the hinge. Several of these created a hydrophobic/aromatic site that the docking algorithm ranked higher than hinge binding interactions. Although the minimization of the target molecule often significantly changed the outcome, there is no overall correlation with respect to the quality of the prediction. The proton assignment could be decisive: Unfavorable assignment of the protonation state of indazole-18 search prevented correct docking. The homology models performed diversely: the ROCK1 model (based on 1q8w) was as good as the best ROCK1 structures, while the PKA homology model was quite poor.

2.2.4. Water and structural variability

Analogous to the problem of treating protein flexibility, the mobilities and potential bridging functions of water in ligand binding pose a serious challenge to structural methods to predict ligand binding [42–44]; SAR analyses of filling a pocket may be complicated by the displacement of a water molecule and partial cavity formation and unfavorable energetics. Analysis of target similarity is less severely impacted, as targets with similar geometric and electrostatic properties would be likely to share similar effects of solvent, even if these are unpredictable. But side chain and other flexibilities determine solvent positions. So, as with flexibility, multiple structure determinations with varying conditions and ligands enable the identification of conserved water positions [45]. Aurora kinases have shown clusters of water; some of these have evolved into distributions. One cluster may be observed in a deep pocket between ATP, the gatekeeper, and the aspartic acid of the DFG

A

	3nc	3nd	Fasudil	H1152P	OH-Fasudil	Indazole-18	RK11342	Staurosporine	Y27632	YB-15-QD37
1Q8W	Light Green	Light Green	Light Green							
PKA Model	Light Green	Light Green	Light Green							
1STC	Light Green	Light Green	Light Green							
1SVG	Light Green	Light Green	Light Green							
2GNJ	Light Green	Light Green	Light Green							
2GNL	Light Green	Light Green	Light Green							
2GNF	Light Green	Light Green	Light Green							
2GNH	Light Green	Light Green	Light Green							
2GNI	Light Green	Light Green	Light Green							
2ESM	Light Green	Light Green	Light Green							
2F2U	Light Green	Light Green	Light Green							
3NCZ	Light Green	Light Green	Light Green							
ROCK1 Model	Light Green	Light Green	Light Green							
3V8S	Light Green	Light Green	Light Green							
4W7P	Light Green	Light Green	Light Green							

B




Fig. 5. Docking of Rho kinase inhibitors to ROCK1, PKA, and PKA-ROCK1 hybrid target structures. a) Overall results. Each target structure (in rows) was used with (bottom half of row) and without (top half of row) minimization. Inhibitors with multiple possible charge or protonation states have multiple columns. Hatching indicates that the inhibitor was extracted from that target structure. The degree to which the energy minimum docked pose is correct is shown by color. Green indicates that the inhibitor was extracted from that target structure. Light green indicates that the hinge-binding moiety is correctly docked, but not all of the molecule. Yellow indicates that the inhibitor docked at the hinge, but in the incorrect pose. Red indicates that the minimum energy docked pose was not at the hinge. Black indicates that there was no docked solution found at all. b) The failure of docking in target structure 1SVG arises from the extended definition of the binding site grid from the native inhibitor (yellow). Without constraints to explicitly require binding at the hinge (white sticks), the minimum energy docking poses place the fasudil variants (purple) near the tip of the glycine-rich loop, where the binding pocket is bounded by residues rich in aromatic side chains (cyan).

segment of the activation loop (Fig. 6a). While strategies to replace this water molecule with a corresponding polar group might be successful, superposition of inhibitor complexes with Aurora show that this pocket may be eliminated entirely by breaking the salt bridge made by the catalytic lysine residue with the helix C glutamic acid and displacing the residues (Fig. 6b).

2.3. Similarity by cheminformatics: calibrating sequence and structure?

Ultimately, it seems, the complexities and many uncertainties of structural analysis will be dealt with by automated application of empirical data. The growing set of computational algorithms for calculating hundreds or thousands of molecular properties increasingly enables




Fig. 6. Water clusters identified from superpositions of Aurora A structures. A) Spheres with shades of red mark different clusters at or near a pocket found between ATP, the gate-keeper, and the aspartic acid of DFG. B) A view from “inside” the protein, looking into the ATP pocket (with the surface generated for the ATP bound Aurora structure). This view shows how inhibitors can occupy the water cluster site, but no longer as a pocket due to the altered conformation of the active site lysine salt bridge (with hydrogen bonds highlighted as yellow dashes).

machine learning in chemoinformatics. Machine learning methods generally involve building a model of complex data relationships from a training set, validating the model with a test set, and then making predictions. These approaches are used e.g. for predicting binding affinities of protein–ligand complexes from molecular properties but may be generalized to predictions of arbitrary relationships, such as the prediction of ADMET properties. Approaches that are especially relevant to chemoinformatics include Random Forest [46,47], Artificial Neural Networks [48], Support Vector Machine [49], and naïve Bayes classifiers [50]. But no matter what the method, application of empirical methods to large and complex systems remains accurate only when the state of the system is not too far from empirically validated states. It remains to be seen how well such methods may be applied also in kinase selectivity and drug design and repurposing studies [51–58], including biological data as well [59].

Kinase inhibitor profiling is a good test case [60,61]. Although the data may be clearly defined, the types of assays differ qualitatively, the targets used are diverse, and key details may not be accessible for query (by humans or machines). Such details may include substrates,

co-factors, pH, post-translational modifications, statistics of parameter fitting, and so on. One may hope that the data set is so large that these sources of error become statistically distributed in way that multivariate statistics may still find the signal in the noise.

2.3.1. Applications of “activity homology”

Posy et al. of Bristol-Myers Squibb published data derived from over 20,000 compounds [61] in Ambit assays. That extent of data enables the definition of “activity homology”, or “the prior probability that a compound will be active for kinase B given that it is active for kinase A”. This is calculated as the percentage of the inhibitor set of kinase A that inhibits kinase B, and provides an interesting method for evaluating target strength rather than binding patterns.

Fig. 7 shows “activity homology” analyses from the BMS data for three sets of targets. First, activity homologies are plotted for Auroras A and B, and Abl kinase, with kinases ordered along the abscissa descending according to their activity homology with Aurora A. Since the activity homology of a protein kinase with itself is 100%, the yellow green points at 100% mark the position along the abscissa of Aurora B and Abl, respectively. Aurora B has an activity homology of roughly 35% with Aurora A, with Abl at about 15%. Aurora B is more homologous to Aurora A in this measure than Abl, but both show a similar pattern of lower homologies with the kinases on the right (with lowest homology to Aurora A). Also apparent are the many outliers to this pattern for Abl, presumably due to different mechanisms for homology (or inhibitor binding) available to Abl and the outlier kinases that are not available to the Aurora kinases. Another pattern is evident: Aurora B has generally higher activity homology to other kinases than Aurora A, that is, Aurora A is a more idiosyncratic kinase.

Comparisons of Alk, Met, and EGFR, all lung cancer targets, show a different pattern (Fig. 7b). Here the similarity of Alk and Met is evident, as is the dissimilarity of EGFR. For polypharmacological targeting of these three kinases, either exceptional compounds with cross-reactivity for all three must be found, or inhibitors must be designed with “orthogonal” binding mechanisms. Covalent binding to the cysteine found at the gate-keeper + 7 hinge position of EGFR would be such a mechanism [62,63]. Finally, Fig. 7c shows a comparison of targets found to be inhibited by firefly luciferin and derivatives [64]. Many of these fragment-like compounds were found to be selective for Dyrk kinases, but individual derivatives were found to target other seemingly unrelated kinases. A full spectrum of patterns is evident, ranging from the close similarity of Dyrks1A and 1B, to the reversed pattern for Aurora A.

2.4. Applying target similarity to efforts against parasites and infectious disease

The use of target similarity to guide drug repurposing or retargeting is especially significant in key areas of infectious disease, especially tuberculosis, malaria, and other protozoan parasite diseases. Some of the focus here is motivated by a market potential considered to small to support large scale research programs, despite the clear medical need; indeed, widespread tropical diseases may be considered orphan diseases in developed countries [65,66]. With its enormous amount of available information and compounds (many coming off patent), protein kinase inhibition for these applications is promising but distinct in several ways. Primary among these is that non-human target kinases are more likely to have novel features compared to the well established human targets. Therefore, there may be greater need for modification of the known compounds. Closely related to this, selectivity for the disease targets over potential human off-target will be a high priority. Thus, the new target must be similar enough to benefit from a retargeting approach, but different enough to allow for the design of selectivity. This may focus attention on more promiscuous inhibitors or fragments in early discovery processes.




Fig. 7. Activity homology plots for selected sets of kinases: A) Aurora A, Aurora B, and Abl; B) Alk, Met, and EGFR, and C) Dyrk1A, Dyrk1B, ERK7, CK2A1, Aurora B, and Aurora A.

One approach is simply to test known inhibitors for activity. A study performed at GSK [67] screened the approximately 2 million compounds of in-house collection against *P. falciparum*, among which around 13,500 had antiplasmodial activity. They were clustered into different chemotypes, and possible targets were analyzed. 51 possible *P. falciparum* targets were found, 30 of which are proposed to be kinases. In some cases, no obvious target was found in the malaria genome, which presents the possibility that “*P. falciparum* could have essential proteins that are structurally and functionally similar to the human targets yet have no significant primary amino acid homology.” Another example concerns trypanosomiasis: Based on the observation that tyrosine kinase inhibitors could inhibit the diacylglycerol-stimulated endocytosis of transferrin in *T. brucei*, Patel et al. optimized EGFR inhibitors based on tests in full cell cultures [68], with toxicity monitored in parallel, to create a compound with promising antitrypanosomal activity confirmed in mouse model studies. In a similar approach, the Aurora inhibitor Hesperadin was tested and modified for antiproliferative activity against several targets [69]. Also, pyrrolopyrazines, originally being developed as herbicidal agents were found to be effective antiplasmodials. Computational studies revealed kinases as potential targets, observing inhibitory activity against human IRK, RAF-1, Src, TrkA and PfPK5, the plasmodial homolog of human CDK2 [70].

Target based approaches, either at initiation or as a followup from screening as described above, require sequence or structural information. In the case of *M. tuberculosis*, genome sequence analysis found 11 eukaryotic-like Ser/Thr kinases [71,72], with low sequence identity with human kinases but some similarity to the CK1 group [73]. To date, crystal structures of the kinase domains of 5 *Mtb* kinases [18] and other surrogate kinase targets [74] are available for drug design.

Kinomes of *P. falciparum* [75] and protozoan parasites more generally [76] have been characterized, identifying parasite kinases with some 35–60% identity with their human homologues. They differ in several significant ways: large C- and/or N-terminal extensions, insertions in the catalytic domain, and differences in regulatory domain and at the activation site. Some 89–99 kinases have been identified, including 65–80 eukaryotic kinases, and a new group (FIKK) [75,77] exclusively within the Apicomplex phylum [78]. Especially noteworthy is a family of seven calcium-dependent kinases (PfCDPKs) belonging to the CAMK group, absent from mammalian hosts but conserved among apicomplexans [78], including several that are necessary for plasmodial survival [79]. In addition, a family of CMGC protein kinases include seven CDK cognates, some shared among protists (Pfmrk) or apicomplexans. Other “orphan” kinases are not assigned to established subfamilies; one of these (PfPK7) is exclusive to *Plasmodium* spp [78]. Currently, 5 different *P. falciparum* protein kinase crystal structures are available on the PDB [18], along with 7 other structures for different apicomplexa organisms. Reviews on kinase targets of interest for *P. falciparum* [80] and approaches to inhibition have been published [79,81].

The PfCDPKs have been of special interest as targets for the development of antimicrobials against malaria, in part because they lack a human homolog. Lead compounds have been identified through screening [82–85].

An alternative way of exploiting the exclusivity of CDPK targets to apicomplexa has been demonstrated by Vidadala et al. [86]. They developed a series of pyrazolopyrimidines that display important selectivity against *Toxoplasma gondii* and *Crtyptosporidium parvum* CDPK1s based on the observation of a glycine at the gatekeeper position (which does not occur in the human kinome, see Fig. 1) and on binding to an adjacent “ribose pocket” [87].

The kinase profiling data of Davis et al. [16] included kinase domains from three pathogen targets, one from *M. tuberculosis* (PKNB), and two from *P. falciparum* (PfCDPK1 and PfPK5). As described above, high correlations of the apparent inhibitor binding energies for the same series of inhibitors compared for two targets should reflect average (dynamic) structural similarity. Fig. 8 shows the correlations of the

inhibitors of the three pathogen targets with the human kinases in the panel. For PKNB, there is a rather broadly distributed similarity, with PAK4 and PAK5 having the highest values. For PfCDPK1, there is low similarity. In contrast to these, PfPK5 shows clearly clustered similarity with CDK2 kinases, and a few other kinases in the CAMK and STE groups.

3. Methods

Pseudosequence similarities between protein kinases were calculated using the Needleman–Wunsch similarity algorithm as implemented in Mathematica (www.wolframresearch.com), with a prohibitive gap penalty (100) and the Blosom62 matrix for similarity scoring. The pseudosequence used for the plots of this manuscript was chosen from the kinase residues that align with the following PKA residues 49, 54, 57, 72, 91, 95, 104, 120, 122, 123, 127, 170, 171, 173, and 183. These correspond to the initiator of the glycine-rich loop and partial “ceiling” of the adenine site (Leu49), the typically aromatic amino acid at the tip of the glycine-rich loop (Phe54), the terminator of the glycine-rich loop and partial “ceiling” of the adenine site (Val57), the innermost side chain of helix C that extends toward the ATP site (Leu95), the ATP site directed side chain of the alpha4-helix C loop (Val104 of the “molecular brake” assembly), the gatekeeper (Met120), the gatekeeper + 2 and + 3 residues at the hinge (Y122; the gatekeeper + 1 residue is highly conserved as Glu and lacks discriminatory power), the gatekeeper + 7 residue (Glu127; often responsible for substrate and inhibitor specificity), Glu170 at the entrance to the ATP site (also a substrate specificity determinant), (Asn171 near the phosphate binding sites), and Leu173 and Thr183 at the base of the adenine binding site. The sequence alignment [13] was downloaded from kinase.com.

Inhibitor correlation plots were generated from the published Ambit data profiling of 72 inhibitors against a panel of over 400 protein kinases [16]. Logarithms of the published Ki values were calculated to obtain values proportional to binding energies, and Pearson's correlation coefficients for pairs of kinases were calculated with Mathematica using the respective vectors of logarithmic inhibition values.

The Schrodinger software suite (www.schrodinger.com) was used for docking Rock1 inhibitors. The target structures chosen were as follows: ROCK1 (PDB ID: 2ESM [88], PDB ID: 2F2U [89], PDB ID: 3NCZ [90], PDB ID: 3V8S [91], PDB ID: 4W7P [92]); a five-fold mutant PKA model [93] for ROCK1 (PDB ID: 2GNH, PDB ID: 2GNI, PDB ID: 2GNF), a three-fold mutant PKA model [93] for ROCK1 (PDB ID: 2GNJ, PDB ID: 2GNL), and native PKA (PDB ID: 1STC [39], PDB ID: 1SVG [94], PDB ID: 1Q8W [95]). The following ligands used for docking were taken from these structures (see Fig. 5a): fasudil, hydroxyfasudil, Y27632, H1152P, 3NC, 3ND, indazole compound 18, RK11342, YB-15-QD37, and staurosporine.

Two homology models were generated (using Schrodinger and its PRIME modeling package), one for Rock1 using PKA structure PDB ID: 1Q8W as a template, and one for PKA using Rock1 structure 3NCZ as a template. The models were subjected to H-bond optimization and restrained minimization. For docking, the target structures were first preprocessed, missing side chains were added if required, water molecules were removed unless they were important as H-bond bridges between two or more side chains. Het-states were generated with the S2 state chosen by default. H-bonds were optimized, followed by restrained minimization. Receptor grids were generated from the bound ligand for the protein–inhibitor complex structures, and by specific amino acid definitions in the apo homology model structures. The ligands were extracted from the structures, and the target structures were then subjected to energy minimization. The ligands were analyzed for potential variations in charge and protonation states (Ligprep), with one or two forms generated for each inhibitor (Fig. 5A). The inhibitors were docked individually into both the minimized and unminimized




Fig. 8. Based on correlations of inhibitor binding energies, the similarities of human protein kinases to A) *M. tuberculosis* PknB, B) *P. falciparum* PfCDPK1, and C) *P. falciparum* PfPK5.

targets structures, whereby all rotatable groups were allowed to rotate. The docking was carried out without any constraints, first in “standard precision” (SP) mode and then the poses were subjected to “extra precision” (XP) mode.

Transparency document

The [Transparency document](#) associated with this article can be found, in the online version.

Acknowledgements

We gratefully acknowledge financial support from the Norwegian Research Council and the Norwegian Cancer Society for this work. V. Tello-Franco gratefully acknowledges support from grant number 232128 from CONACYT (Mexico).

References

- [1] D.R. Knighton, J.H. Zheng, L.F. Ten Eyck, V.A. Ashford, N.H. Xuong, S.S. Taylor, et al., Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase, *Science* 253 (5018) (Jul 26 1991) 407–414.
- [2] S.R. Hubbard, L. Wei, W.A. Hendrickson, Crystal structure of the tyrosine kinase domain of the human insulin receptor, *Nature* 372 (6508) (Dec 29 1994) 746–754.
- [3] T. Asano, T. Suzuki, M. Tsuchiya, S. Satoh, I. Ikegaki, M. Shibuya, et al., Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase, *Br. J. Pharmacol.* 98 (4) (Dec 1989) 1091–1100.
- [4] M.H. Cohen, G. Williams, J.R. Johnson, J. Duan, J. Gobburu, A. Rahman, et al., Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia, *Clin. Cancer Res.* 8 (5) (May 1 2002) 935–942.
- [5] T. Hunter, Treatment for chronic myelogenous leukemia: the long road to imatinib, *J. Clin. Invest.* 117 (8) (Aug 1 2007) 2036–2043.
- [6] Z.A. Knight, H. Lin, K.M. Shokat, Targeting the cancer kinome through polypharmacology, *Nat. Rev. Cancer* 10 (2) (Feb 2010) 130–137.
- [7] E. Martin, P. Mukherjee, Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome, *J. Chem. Inf. Model.* 52 (1) (Jan 23 2012) 156–170.
- [8] J.R. Miller, S. Dunham, I. Mochalkin, C. Banotai, M. Bowman, S. Buist, et al., A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore, *Proc. Natl. Acad. Sci. U. S. A.* 106 (6) (Feb 10 2009) 1737–1742.
- [9] C.J. Harris, R.D. Hill, D.W. Sheppard, M.J. Slater, P.F.W. Stouten, The design and application of target-focused compound libraries, *Comb. Chem. High Throughput Screen.* 14 (6) (Jul 2011) 521–531.
- [10] S. Hess, The emerging field of chemo- and pharmacoproteomics, *Proteomics Clin. Appl.* 7 (1–2) (Jan 2013) 171–180.
- [11] A.C. Dar, T.K. Das, K.M. Shokat, R.L. Cagan, Chemical genetic discovery of targets and anti-targets for cancer polypharmacology, *Nature* 486 (7401) (Jun 7 2012) 80–84.
- [12] T. Lundqvist, The devil is still in the details—driving early drug discovery forward with biophysical experimental methods, *Curr. Opin. Drug Discov. Devel.* 8 (4) (Jul 2005) 513–519.
- [13] G. Manning, D.B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, The protein kinase complement of the human genome, *Science* 298 (5600) (Dec 6 2002) 1912–1934.
- [14] F.X. Gruber, T. Ernst, K. Porkka, R.A. Engh, I. Mikkola, J. Maier, et al., Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients, *Leukemia* 26 (1) (Jan 2012) 172–177, <http://dx.doi.org/10.1038/leu.2011.187> (Epub 2011 Aug 5).
- [15] D. Bossemeyer, R.A. Engh, V. Kinzel, H. Ponstingl, R. Huber, Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 Å structure of the complex with Mn²⁺ adenylyl imidodiphosphate and inhibitor peptide PKI(5–24), *EMBO J.* 12 (3) (Mar 1993) 849–859.
- [16] M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, G. Pallares, et al., Comprehensive analysis of kinase inhibitor selectivity, *Nat. Biotechnol.* 29 (11) (Nov 2011) 1046–1051.
- [17] H. Berman, K. Henrick, H. Nakamura, Announcing the worldwide Protein Data Bank, *Nat. Struct. Mol. Biol.* 10 (12) (Dec 2003) 980–980.
- [18] H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, et al., The Protein Data Bank, *Nucleic Acids Res.* 28 (1) (Jan 1 2000) 235–242.
- [19] F. Moriaud, S.B. Richard, S.A. Adcock, L. Chanas-Martin, J.-S. Surgand, M. Ben Jelloul, et al., Identify drug repurposing candidates by mining the protein data bank, *Brief. Bioinform.* 12 (4) (Jul 2011) 336–340.
- [20] F. Milletti, A. Vulpetti, Predicting polypharmacology by binding site similarity: from kinases to the protein universe, *J. Chem. Inf. Model.* 50 (8) (Aug 23 2010) 1418–1431.
- [21] A.M. Traynor, M. Hewitt, G. Liu, K.T. Flaherty, J. Clark, S.J. Freedman, et al., Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors, *Cancer Chemother. Pharmacol.* 67 (2) (Feb 2011) 305–314.
- [22] F.J. Giles, R.T. Swords, A. Nagler, A. Hochhaus, O.G. Ottmann, D.A. Rizzieri, et al., MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia, *Leukemia* 27 (1) (Jan 2013) 113–117.
- [23] J.F. Seymour, D.W. Kim, E. Rubin, A. Haregewoin, J. Clark, P. Watson, et al., A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, *Blood Cancer J.* 4 (2014) e238.
- [24] S. Okabe, T. Tauchi, K. Ohyashiki, Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells, *Ann. Hematol.* 89 (11) (Nov 2010) 1081–1087.
- [25] T.M. Oliveira, R. Ahmad, R.A. Engh, VX680 binding in Aurora A: π - π interactions involving the conserved aromatic amino acid of the flexible glycine-rich loop, *J. Phys. Chem. A* 115 (16) (Apr 2011) 3895–3904.
- [26] O.A.B.S.M. Gani, D. Narayanan, R.A. Engh, Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistance, *Chem. Biol. Drug Des.* 82 (5) (Nov 2013) 506–519.
- [27] M.A. Young, N.P. Shah, L.H. Chao, M. Seeliger, Z.V. Milanov, W.H. Biggs, et al., Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680, *Cancer Res.* 66 (2) (Jan 15 2006) 1007–1014.
- [28] B. Zhao, A. Smallwood, J. Yang, K. Koretke, K. Nurse, A. Calamari, et al., Modulation of kinase-inhibitor interactions by auxiliary protein binding: Crystallography studies on Aurora A interactions with VX-680 and with TPX2, *Protein Sci.* 17 (10) (2008) 1791–1797.
- [29] E. Salah, E. Ugochukwu, A.J. Barr, F. von Delft, S. Knapp, J.M. Elkins, Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class, *J. Med. Chem.* 54 (7) (Apr 14 2011) 2359–2367.
- [30] J.-M. Wu, C.-T. Chen, M.S. Coumar, W.-H. Lin, Z.-J. Chen, J.T.-A. Hsu, et al., Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules, *Proc. Natl. Acad. Sci. U. S. A.* 110 (19) (May 7 2013) E1779–E1787.
- [31] J.M. Elkins, S. Santaguida, A. Musacchio, S. Knapp, Crystal structure of human aurora B in complex with INCENP and VX-680, *J. Med. Chem.* 55 (17) (Sep 13 2012) 7841–7848.
- [32] A. Pflug, T.M. de Oliveira, D. Bossemeyer, R.A. Engh, Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase, *Biochem. J.* 440 (1) (Nov 15 2011) 85–93, <http://dx.doi.org/10.1042/BJ20110592>.
- [33] J.J. Cui, M. Tran-Dubé, H. Shen, M. Nambu, P.-P. Kung, M. Pairish, et al., Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK), *J. Med. Chem.* 54 (18) (Sep 22 2011) 6342–6363.
- [34] Q. Huang, T.W. Johnson, S. Bailey, A. Brooun, K.D. Bunker, B.J. Burke, et al., Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib, *J. Med. Chem.* 57 (4) (Feb 27 2014) 1170–1187.
- [35] T. Tuccinardi, M. Botta, A. Giordano, A. Martinelli, Protein kinases: docking and homology modeling reliability, *J. Chem. Inf. Model.* 50 (8) (Aug 23 2010) 1432–1441.
- [36] Y.-C. Chen, Beware of docking! *Trends Pharmacol. Sci.* 36 (2) (Feb 2015) 78–95.
- [37] L. Krippahl, P. Barahona, Protein docking with predicted constraints, *Algorithms Mol. Biol.* 10 (2015) 9.
- [38] W.M. Rockey, A.H. Elcock, Structure selection for protein kinase docking and virtual screening: homology models or crystal structures? *Curr. Protein Pept. Sci.* 7 (5) (Oct 2006) 437–457.
- [39] L. Prade, R.A. Engh, A. Girod, V. Kinzel, R. Huber, D. Bossemeyer, Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential, *Structure* 5 (12) (Dec 1997) 1627–1637.
- [40] C.N. Cavasotto, R.A. Abagyan, Protein flexibility in ligand docking and virtual screening to protein kinases, *J. Mol. Biol.* 337 (1) (Mar 12 2004) 209–225.
- [41] C. Sotriffer, Virtual Screening: Principles, Challenges, and Practical Guidelines, John Wiley & Sons, 2011. (543 p.).
- [42] H. Sun, L. Zhao, S. Peng, N. Huang, Incorporating replacement free energy of binding-site waters in molecular docking, *Proteins* 82 (9) (Sep 2014) 1765–1776.
- [43] S. Barelrier, S.E. Boyce, I. Fish, M. Fischer, D.B. Goodin, B.K. Shoichet, Roles for ordered and bulk solvent in ligand recognition and docking in two related cavities, *PLoS One* 8 (7) (2013) e69153.
- [44] J. Michel, J. Tirado-Rives, W.L. Jorgensen, Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization, *J. Am. Chem. Soc.* 131 (42) (Oct 28 2009) 15403–15411.
- [45] C. Barillari, A.L. Duncan, I.M. Westwood, J. Blagg, R.L.M. van Montfort, Analysis of water patterns in protein kinase binding sites, *Proteins* 79 (7) (Jul 2011) 2109–2121.
- [46] L. Breiman, Random Forests, *Mach. Learn.* 45 (1) (Oct 1 2001) 5–32.
- [47] V. Svetnik, A. Liaw, C. Tong, J.C. Culberson, R.P. Sheridan, B.P. Feuston, Random forest: a classification and regression tool for compound classification and QSAR modeling, *J. Chem. Inf. Comput. Sci.* 43 (6) (Dec 2003) 1947–1958.
- [48] H. Briem, J. Günther, Classifying “kinase inhibitor-likeness” by using machine-learning methods, *Chembiochem* 6 (3) (Mar 2005) 558–566.
- [49] W.S. Noble, What is a support vector machine? *Nat. Biotechnol.* 24 (12) (Dec 2006) 1565–1567.
- [50] A. Bender, Bayesian methods in virtual screening and chemical biology, *Methods Mol. Biol.* 672 (2011) 175–196.
- [51] O. Méndez-Lucio, A.J. Kooistra, C. de Graaf, A. Bender, J.L. Medina-Franco, Analyzing Multitarget Activity Landscapes Using Protein–Ligand Interaction Fingerprints: Interaction Cliffs, *J. Chem. Inf. Model.* 55 (2) (Feb 23 2015) 251–262.
- [52] L. Siragusa, S. Cross, M. Baroni, L. Goracci, G. Cruciani, BioGPS: Navigating biological space to predict polypharmacology, off-targeting, and selectivity, *Proteins* 83 (3) (Mar 2015) 517–532.
- [53] V. Subramanian, P. Prusis, L.-O. Pietilä, H. Xhaard, G. Wohlfahrt, Visually interpretable models of kinase selectivity related features derived from field-based proteochemometrics, *J. Chem. Inf. Model.* 53 (11) (Nov 25 2013) 3021–3030.
- [54] S.S. Phatak, S. Zhang, A novel multi-modal drug repurposing approach for identification of potent ACK1 inhibitors, *Pac. Symp. Biocomput.* (2013) 29–40.
- [55] T. Liu, R.B. Altman, Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding, *PLoS Comput. Biol.* 7 (12) (Dec 2011) e1002326.
- [56] Y. Gao, S.P. Davies, M. Augustin, A. Woodward, U.A. Patel, R. Kovelman, et al., A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery, *Biochem. J.* 451 (2) (Apr 15 2013) 313–328.
- [57] F. Cheng, Y. Zhou, J. Li, W. Li, G. Liu, Y. Tang, Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods, *Mol. BioSyst.* 8 (9) (Sep 2012) 2373–2384.

- [58] F. Cheng, Y. Zhou, W. Li, G. Liu, Y. Tang, Prediction of chemical–protein interactions network with weighted network-based inference method, *PLoS One* 7 (7) (2012) e41064.
- [59] F. Iorio, R. Bosotti, E. Scacheri, V. Belcastro, P. Mithbaokar, R. Ferriero, et al., Discovery of drug mode of action and drug repositioning from transcriptional responses, *Proc. Natl. Acad. Sci. U. S. A.* 107 (33) (Aug 17 2010) 14621–14626.
- [60] J.J. Sutherland, C. Gao, S. Cahya, M. Vieth, What general conclusions can we draw from kinase profiling data sets? *Biochim. Biophys. Acta* 1834 (7) (Jul 2013) 1425–1433.
- [61] S.L. Posy, M.A. Hermsmeier, W. Vaccaro, K.-H. Ott, G. Todderud, J.S. Lippy, et al., Trends in kinase selectivity: insights for target class-focused library screening, *J. Med. Chem.* 54 (1) (Jan 13 2011) 54–66.
- [62] E. Leproult, S. Barluenga, D. Moras, J.-M. Wurtz, N. Winssinger, Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors, *J. Med. Chem.* 54 (5) (Mar 10 2011) 1347–1355.
- [63] Q. Liu, Y. Sabnis, Z. Zhao, T. Zhang, S.J. Buhrlage, L.H. Jones, et al., Developing irreversible inhibitors of the protein kinase cysteinome, *Chem. Biol.* 20 (2) (Feb 21 2013) 146–159.
- [64] U. Rothweiler, J. Eriksson, W. Stensen, F. Leeson, R.A. Engh, J.S. Svendsen, Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors, *Eur. J. Med. Chem.* 94 (Apr 13 2015) 140–148.
- [65] M. Allarakhia, Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases, *Drug Des. Devel. Ther.* 7 (Aug 8 2013) 753–766.
- [66] R. Muthyala, Orphan/rare drug discovery through drug repositioning, *Drug Discov. Today Ther. Strateg.* 8 (3–4) (2011) 71–76.
- [67] F.-J. Gamo, L.M. Sanz, J. Vidal, C. de Cozar, E. Alvarez, J.-L. Lavandera, et al., Thousands of chemical starting points for antimalarial lead identification, *Nature* 465 (7296) (May 20 2010) 305–310.
- [68] G. Patel, C.E. Karver, R. Behera, P.J. Guyett, C. Sullenberger, P. Edwards, et al., Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis, *J. Med. Chem.* 56 (10) (May 23 2013) 3820–3832.
- [69] G. Patel, N.E. Roncal, P.J. Lee, S.E. Leed, J. Erath, A. Rodriguez, et al., Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery, *Med. Chem. Commun.* 5 (5) (May 1 2014) 655–658.
- [70] D. Reker, M. Seet, M. Pillong, C.P. Koch, P. Schneider, M.C. Witschel, et al., Deorphaning pyrrolopyrazines as potent multi-target antimalarial agents, *Angew. Chem. Int. Ed. Engl.* 53 (27) (Jul 1 2014) 7079–7084.
- [71] S.T. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, et al., Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence, *Nature* 393 (6685) (Jun 11 1998) 537–544.
- [72] Y. Av-Gay, M. Everett, The eukaryotic-like Ser/Thr protein kinases of *Mycobacterium tuberculosis*, *Trends Microbiol.* 8 (5) (May 2000) 238–244.
- [73] A. Wehenkel, M. Bellinzoni, M. Graña, R. Duran, A. Villarino, P. Fernandez, et al., Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential, *Biochim. Biophys. Acta* 1784 (1) (Jan 2008) 193–202.
- [74] L. Baugh, I. Phan, D.W. Begley, M.C. Clifton, B. Armour, D.M. Dranow, et al., Increasing the structural coverage of tuberculosis drug targets, *Tuberculosis (Edinb.)* 95 (2) (Mar 2015) 142–148, <http://dx.doi.org/10.1016/j.tube.2014.12.003>.
- [75] P. Ward, L. Equinet, J. Packer, C. Doerig, Protein kinases of the human malaria parasite *Plasmodium falciparum*: the kinome of a divergent eukaryote, *BMC Genomics* 5 (Oct 12 2004) 79.
- [76] C. Doerig, Protein kinases as targets for anti-parasitic chemotherapy, *Biochim. Biophys. Acta* 1697 (1–2) (Mar 11 2004) 155–168.
- [77] Anamika, N. Srinivasan, A. Krupa, A genomic perspective of protein kinases in *Plasmodium falciparum*, *Proteins* 58 (1) (Jan 1 2005) 180–189.
- [78] D. Miranda-Saavedra, T. Gabaldón, G.J. Barton, G. Langsley, C. Doerig, The kinomes of apicomplexan parasites, *Microbes Infect.* 14 (10) (Aug 2012) 796–810.
- [79] V.M. Zhang, M. Chavchich, N.C. Waters, Targeting protein kinases in the malaria parasite: update of an antimalarial drug target, *Curr. Top. Med. Chem.* 12 (5) (2012) 456–472.
- [80] C. Doerig, A. Abdi, N. Bland, S. Eschenlauer, D. Dorin-Semlat, C. Fennell, et al., Malaria: targeting parasite and host cell kinomes, *Biochim. Biophys. Acta* 1804 (3) (Mar 2010) 604–612.
- [81] D.P. Rotella, Recent results in protein kinase inhibition for tropical diseases, *Bioorg. Med. Chem. Lett.* 22 (22) (Nov 15 2012) 6788–6793.
- [82] N. Kato, T. Sakata, G. Breton, K.G. Le Roch, A. Nagle, C. Andersen, et al., Gene expression signatures and small-molecule compounds link a protein kinase to *Plasmodium falciparum* motility, *Nat. Chem. Biol.* 4 (6) (Jun 2008) 347–356.
- [83] G. Lemerrier, A. Fernandez-Montalvan, J.P. Shaw, D. Kugelstadt, J. Bomke, M. Domostoj, et al., Identification and characterization of novel small molecules as potent inhibitors of the plasmodial calcium-dependent protein kinase 1, *Biochemistry (Mosc)* 48 (27) (Jul 14 2009) 6379–6389.
- [84] T.M. Chapman, S.A. Osborne, C. Wallace, K. Birchall, N. Bouloc, H.M. Jones, et al., Optimization of an imidazopyridazine series of inhibitors of *Plasmodium falciparum* calcium-dependent protein kinase 1 (PfCDPK1), *J. Med. Chem.* 57 (8) (Apr 24 2014) 3570–3587.
- [85] T.M. Chapman, S.A. Osborne, N. Bouloc, J.M. Large, C. Wallace, K. Birchall, et al., Substituted imidazopyridazines are potent and selective inhibitors of *Plasmodium falciparum* calcium-dependent protein kinase 1 (PfCDPK1), *Bioorg. Med. Chem. Lett.* 23 (10) (May 15 2013) 3064–3069.
- [86] R.S.R. Vidadala, K.K. Ojo, S.M. Johnson, Z. Zhang, S.E. Leonard, A. Mitra, et al., Development of potent and selective *Plasmodium falciparum* calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes, *Eur. J. Med. Chem.* 74 (Mar 3 2014) 562–573.
- [87] E.T. Larson, K.K. Ojo, R.C. Murphy, S.M. Johnson, Z. Zhang, J.E. Kim, et al., Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1, *J. Med. Chem.* 55 (6) (Mar 22 2012) 2803–2810.
- [88] M. Jacobs, K. Hayakawa, L. Swenson, S. Bellon, M. Fleming, P. Taslimi, et al., The structure of dimeric ROCK 1 reveals the mechanism for ligand selectivity, *J. Biol. Chem.* 281 (1) (Jan 6 2006) 260–268.
- [89] H. Yamaguchi, M. Kasa, M. Amano, K. Kaibuchi, T. Hakoshima, Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil, *Structure* 14 (3) (Mar 2006) 589–600.
- [90] J.D. Ginn, T. Bosanac, R. Chen, C. Cywin, E. Hickey, M. Kashem, et al., Substituted 2H-isouquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive rats, *Bioorg. Med. Chem. Lett.* 20 (17) (Sep 1 2010) 5153–5156.
- [91] R. Li, M.P. Martin, Y. Liu, B. Wang, R.A. Patel, J.-Y. Zhu, et al., Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors, *J. Med. Chem.* 55 (5) (Mar 8 2012) 2474–2478.
- [92] D. Shaw, G. Hollingworth, N. Soldermann, E. Sprague, W. Schuler, E. Vangrevelinghe, et al., Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension, *Bioorg. Med. Chem. Lett.* 24 (20) (Oct 15 2014) 4812–4817.
- [93] S. Bonn, S. Herrero, C.B. Breitenlechner, A. Erlbruch, W. Lehmann, R.A. Engh, et al., Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity, *J. Biol. Chem.* 281 (34) (2006) 24818–24830.
- [94] C.B. Breitenlechner, T. Wegge, L. Berillon, K. Graul, K. Marzenell, W.-G. Friebe, et al., Structure-based optimization of novel azepane derivatives as PKB inhibitors, *J. Med. Chem.* 47 (6) (2004) 1375–1390.
- [95] C. Breitenlechner, M. Gassel, H. Hidaka, V. Kinzel, R. Huber, R.A. Engh, et al., Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity, *Structure* 11 (12) (Dec 2003) 1595–1607.